ReviewFrontiers in microbiology2019
Bioactive Peptides Against Fungal Biofilms.
Review in Frontiers in microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05368948 (The Assessment of Antimicrobial Peptides Against Fungal Infection), which is not on this map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Assessment of Antimicrobial Peptides Against Fungal Infection
Who cites it
39 citing papers in PubMed.
- Morphotype-specific susceptibility toMicrobiology spectrum · 2026Article
- Role of antimicrobial peptide-based biomaterials in respiratory tract infections control.BMC microbiology · 2026Review
- Smart Antibiofilm Platforms Based on Synthetic Antimicrobial Peptides-Engineered Hydrogels.Polymers · 2026Review
- Repositioning Antimicrobial Peptides Against WHO-Priority Fungi.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Self-assembled nanopeptide dendrites with high antifungal activity and protease hydrolytic stability for fungal keratitis treatment.Journal of nanobiotechnology · 2025Article
- Reducing Functional Domain of Histatin 5 Improves Antifungal Activity and Prevents Proteolytic Degradation.Microorganisms · 2025Article
- Antibiofilm Activities of Tritrpticin Analogs Against PathogenicMolecules (Basel, Switzerland) · 2025Article
- Biofilm Resilience: Molecular Mechanisms Driving Antibiotic Resistance in Clinical Contexts.Biology · 2025Review
- Antifungal Innate Immunity.Advances in experimental medicine and biology · 2025Review
- Conjugation of CRAMPInternational journal of molecular sciences · 2024Article
- Discovery of Melittin as Triple-Action Agent: Broad-Spectrum Antibacterial, Anti-Biofilm, and Potential Anti-Quorum Sensing Activities.Molecules (Basel, Switzerland) · 2024Article
- Exploring the frontiers of therapeutic breadth of antifungal peptides: A new avenue in antifungal drugs.Journal of industrial microbiology & biotechnology · 2024Review
- Two promisingFrontiers in pharmacology · 2024Article
- Article
- Antifungal properties of cathelicidin LL-37: current knowledge and future research directions.World journal of microbiology & biotechnology · 2023Review
- Recent advances in the development of therapeutic peptides.Trends in pharmacological sciences · 2023Review
- Novel Arginine- and Proline-Rich Candidacidal Peptides Obtained through a Bioinformatic Approach.Antibiotics (Basel, Switzerland) · 2023Article
- Reversal of Azole Resistance inBiomedicines · 2023Article
- Embedded-AMP: A Multi-Thread Computational Method for the Systematic Identification of Antimicrobial Peptides Embedded in Proteome Sequences.Antibiotics (Basel, Switzerland) · 2023Article
- Characterization and expression of fungal defensin inFrontiers in microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infections caused by invasive fungal biofilms have been widely associated with high morbidity and mortality rates, mainly due to the advent of antibiotic resistance. Moreover, fungal biofilms impose an additional challenge, leading to multidrug resistance. This fact, along with the contamination of medical devices and the limited number of effective antifungal agents available on the market, demonstrates the importance of finding novel drug candidates targeting pathogenic fungal cells and biofilms. In this context, an alternative strategy is the use of antifungal peptides (AFPs) against fungal biofilms. AFPs are considered a group of bioactive molecules with broad-spectrum activities and multiple mechanisms of action that have been widely used as template molecules for drug design strategies aiming at greater specificity and biological efficacy. Among the AFP classes most studied in the context of fungal biofilms, defensins, cathelicidins and histatins have been described. AFPs can also act by preventing the formation of fungal biofilms and eradicating preformed biofilms through mechanisms associated with cell wall perturbation, inhibition of planktonic fungal cells' adhesion onto surfaces, gene regulation and generation of reactive oxygen species (ROS). Thus, considering the critical scenario imposed by fungal biofilms and associated infections and the application of AFPs as a possible treatment, this review will focus on the most effective AFPs described to date, with a core focus on antibiofilm peptides, as well as their efficacy
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.